Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Amarin Corp Ads (NQ: AMRN )

5.020 USD +0.010 (+0.20%)
Streaming Delayed Price Updated: 8:00 AM EDT, Apr 16, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Amarin Corp Ads

< Previous 1 2 3 4 5 6 7 8 9
...
89 90 Next >
4 Reasons Amarin Stock Could Tumble Even Further
The company's second-quarter earnings report was less than encouraging. 
Tags Market News AMRN
From Motley Fool
US Stocks That Surged Higher This Week: $AMRN $NAK $AGEN
Tags The Market Signal
From The Market Signal
Market Briefing For Wednesday, August 5
The pandemic is not over. There is also an epidemic of violence by those who do not grasp the importance of both freedom of expression, free-market capitalism, and what some allege is now... 
Tags Stocks / Equities Pharma/Biotech
From Blogs - TalkMarkets
Amarin (AMRN) Q2 2020 Earnings Call Transcript
AMRN earnings call for the period ending June 30, 2020. 
Tags Market News AMRN
From Motley Fool
Amarin Reports Mixed Q2 As COVID-19 Weighs On Results; Analyst Sees Favorable Risk-Reward
Amarin Corporation plc (NASDAQ: AMRN) shares were advancing strongly Tuesday following the release Tuesday ofsecond-quarter ... 
Tags Biotech Analyst Color Price Target
From Benzinga
Amarin's Vascepa Sales Jump 34% in Q2 Despite COVID-19 Headwinds
The big wild card for the company now is its appeal of a court ruling invalidating key patents for the high triglyceride drug. 
Tags Market News AMRN
From Motley Fool
The Daily Biotech Pulse: Voyager, AbbVie End Collaboration, Thumbs Down For DBV's Peanut Allergy Patch, Tiziana Expedites COVID-19 Trial Plans
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) ABIOMED, Inc. (NASDAQ: ABMD) ALX Oncology Holdings Inc ... 
Tags NBIX Trading Ideas MYOK
From Benzinga
Recap: Amarin Q2 Earnings
Shares of Amarin Corp (NASDAQ:AMRN) rose 2.2% in pre-market trading after the company reported Q2 results. Quarterly ... 
Tags News AMRN Market News
From Benzinga
Amarin Announces Plans to Maximize Blockbuster Potential of VASCEPA® (icosapent ethyl) in Europe
From GlobeNewswire News Releases
Amarin Reports Second Quarter 2020 Financial Results and Provides Update on Operations
From GlobeNewswire News Releases
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical ... 
Tags JAZZ GSK ZGNX
From Benzinga
AMRN September 11th Options Begin Trading
Investors in Amarin Corp plc (AMRN) saw new options begin trading today, for the September 11th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AMRN options... 
Tags Stocks
From Market News Video
VASCEPA® (icosapent ethyl) Data from REDUCE-IT® REVASC, Including New Data on Timeframe to Demonstrated Benefit, Presented as Encore at The American Society for Preventive Cardiology 2020 Virtual Summ
From GlobeNewswire News Releases
Amarin to Report Second Quarter 2020 Results and Host Conference Call on August 4, 2020
From GlobeNewswire News Releases
Analysts Predict 13% Upside For IBB
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Here's Why Amarin Tumbled 67.7% in the First Half of 2020
The pharma stock collapsed on the threat of generic competition for a drug that launched in December 2019, but the move may have been a bit of an overreaction. 
Tags AMRN Market News RDY
From Motley Fool
Wall Street Has Given Up on These 2 Stocks, and That's a Huge Mistake
Why StoneCo and bluebird bio are wonderful buys right now. 
Tags SHOP NVAX STNE
From Motley Fool
Amarin Settlement With Apotex An 'Incremental Positive,' Says Stifel
Stifel analyst Derek Archila reiterates his Hold rating on Amarin shares after the company settled with Apotex regarding its ANDA application for generic Vascepa. 
Tags Stocks / Equities
From Blogs - TalkMarkets
Amarin Analysts Say Vascepa Patent Settlement Not A Stock Mover, With 'Little Readthrough For Pending Patent Appeal'
Amarin Corporation plc (NASDAQ: AMRN) announced late Tuesday a settlement agreement with Apotex for resolving a patent lawsuit regarding ... 
Tags Derek Archila News Stifel
From Benzinga
The Daily Biotech Pulse: Patent Win For Amarin, FDA Nod For Novartis & Merck, Chembio's Coronavirus EUA Revoked
Here's a roundup of top developments in the biotech space over the last 24 hour. Scaling The Peaks (Biotech Stocks Hitting ... 
Tags IDYA TRIL Market News
From Benzinga
40 Stocks Moving in Wednesday's Pre-Market Session
Gainers Energous Corporation (NASDAQ: WATT) shares rose 126.2% to $5.00 in pre-market trading after the company reported a ... 
Tags Pre/Market Outlook UONE MARK
From Benzinga
Market Briefing For Wednesday, June 17
The repeated and projected rallies off the 200-Day Moving Average, would not have been blessed with success if not for favorable news on the COVID-19 front as well as a continually friendly Fed. 
Tags Currencies/Forex ETFs Technology
From Blogs - TalkMarkets
10 Stocks Moving In Tuesday's After-Hours Session
Gainers Fulgent Genetics (NASDAQ: FLGT) shares are trading higher after the company announced it launched an at-home testing ... 
Tags GAN INWK News
From Benzinga
Amarin Announces Patent Litigation Settlement Agreement with Apotex Inc.
From GlobeNewswire News Releases
PPH's Holdings Imply 21% Gain Potential
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
VASCEPA® (icosapent ethyl) Shows Significant Cardiovascular Risk Reduction in People with Diabetes in Prespecified and Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study
From GlobeNewswire News Releases
Amarin Plans to Increase VASCEPA® (icosapent ethyl) Promotion and Education
Significant Opportunity Seen as Patient Visits Resume to Emphasize VASCEPA as the First and Only Drug Approved for Its Current Cardiovascular Risk Reduction Indication 
From GlobeNewswire News Releases
What’s Next For The Biotech Bull Market? Are you a Trader or an Investor?
Despite the economic pains of the pandemic, investors are driven to life science companies in the news with potential solutions for COVID-19. The potential for a COVID-19 vaccine or a new viral... 
Tags Pharma/Biotech Mutual Funds Healthcare
From Blogs - TalkMarkets
FDA Approves Generic Version of Amarin's Blockbuster Fish Oil Capsules
The arrival of a generic version of Vascepa will be bad news for the company. 
Tags RDY HKMPY Market News
From Motley Fool
Generic Threat To Amarin's Vascepa Overrides Positive Sentiment On Coronavirus Announcement
Amarin Corporation plc (NASDAQ: AMRN) shares, which were higher in after-hours trading Thursday following the company's announcement ... 
Tags Reiteration Hikma Biologics SVB Leerink
From Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
89 90 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.